EE200300466A - Püridoindolooni derivaatide kasutamine ravimite valmistamiseks - Google Patents

Püridoindolooni derivaatide kasutamine ravimite valmistamiseks

Info

Publication number
EE200300466A
EE200300466A EEP200300466A EEP200300466A EE200300466A EE 200300466 A EE200300466 A EE 200300466A EE P200300466 A EEP200300466 A EE P200300466A EE P200300466 A EEP200300466 A EE P200300466A EE 200300466 A EE200300466 A EE 200300466A
Authority
EE
Estonia
Prior art keywords
medicaments
preparation
pyridoindolone derivatives
pyridoindolone
derivatives
Prior art date
Application number
EEP200300466A
Other languages
English (en)
Estonian (et)
Inventor
Bourrie Bernard
Casellas Pierre
Derocq Jean-Marie
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200300466A publication Critical patent/EE200300466A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300466A 2001-04-27 2002-04-26 Püridoindolooni derivaatide kasutamine ravimite valmistamiseks EE200300466A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001449 WO2002087574A2 (fr) 2001-04-27 2002-04-26 Utilisation de derives de pyridoindolone pour la preparation de medicaments anticancereux

Publications (1)

Publication Number Publication Date
EE200300466A true EE200300466A (et) 2003-12-15

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200300466A EE200300466A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
EEP200300465A EE200300465A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200300465A EE200300465A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE338548T1 (enExample)
BG (2) BG108261A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2443012C (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ299465B6 (enExample)
DE (2) DE60214533T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
JP2002510686A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
DK1385512T3 (da) 2006-05-22
DE60208365T2 (de) 2006-09-07
EA200301062A1 (ru) 2004-04-29
NO20034787D0 (no) 2003-10-24
KR100847413B1 (ko) 2008-07-18
ES2254683T3 (es) 2006-06-16
RS50790B (sr) 2010-08-31
HUP0400745A2 (hu) 2004-08-30
SK13242003A3 (sk) 2004-03-02
IL158266A (en) 2009-09-01
PT1385512E (pt) 2006-05-31
BR0209138A (pt) 2004-06-08
DE60214533D1 (de) 2006-10-19
FR2823975A1 (fr) 2002-10-31
BG108260A (bg) 2004-12-30
US20050272760A1 (en) 2005-12-08
CY1105813T1 (el) 2011-02-02
EP1385512B1 (fr) 2005-12-28
IS2441B (is) 2008-11-15
HUP0400744A2 (hu) 2004-06-28
CZ20032910A3 (en) 2004-07-14
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
IL158312A0 (en) 2004-05-12
HK1060066A1 (en) 2004-07-30
ZA200307785B (en) 2004-10-06
CN1505510A (zh) 2004-06-16
UA74876C2 (en) 2006-02-15
RS50791B (sr) 2010-08-31
EP1385513A1 (fr) 2004-02-04
JP2004528343A (ja) 2004-09-16
EA005930B1 (ru) 2005-08-25
WO2002087574A3 (fr) 2003-02-13
ES2271264T3 (es) 2007-04-16
CN1240382C (zh) 2006-02-08
YU83403A (sh) 2006-08-17
US20040122027A1 (en) 2004-06-24
PL366916A1 (en) 2005-02-07
US20040122036A1 (en) 2004-06-24
YU83903A (sh) 2006-08-17
NO20034787L (no) 2003-12-23
NZ528671A (en) 2004-06-25
IL158312A (en) 2009-09-01
CA2443012C (fr) 2009-07-28
PL366910A1 (en) 2005-02-07
MXPA03009639A (es) 2004-06-30
US6967203B2 (en) 2005-11-22
US7160895B2 (en) 2007-01-09
SK13252003A3 (sk) 2004-03-02
DK1385513T3 (da) 2007-01-15
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
NO20034785D0 (no) 2003-10-24
WO2002087575A1 (fr) 2002-11-07
EE200300465A (et) 2003-12-15
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
CN1505511A (zh) 2004-06-16
DE60214533T2 (de) 2007-06-21
CZ20032909A3 (en) 2004-06-16
CA2443012A1 (en) 2002-11-07
HK1059895A1 (en) 2004-07-23
CZ295224B6 (cs) 2005-06-15
US7524857B2 (en) 2009-04-28
ATE314070T1 (de) 2006-01-15
RU2292888C2 (ru) 2007-02-10
RU2003130376A (ru) 2005-04-10
CA2444334A1 (fr) 2002-11-07
PT1385513E (pt) 2007-01-31
EP1385513B1 (fr) 2006-09-06
JP2004531538A (ja) 2004-10-14
KR20040015138A (ko) 2004-02-18
AR034313A1 (es) 2004-02-18
CZ299465B6 (cs) 2008-08-06
IS6984A (is) 2003-10-09
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07

Similar Documents

Publication Publication Date Title
EE05643B1 (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
NO20033384D0 (no) Farmasöytisk formulering
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
NO20033785D0 (no) Farmasöytisk formulering
ITTO20010008A0 (it) Formulazione farmaceutica
ATE314069T1 (de) Antineoplasische kombinationspräparate
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
DE60208622D1 (de) Siliciumoxidpulver und dessen Herstellung
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200300048A (et) Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine
IL161885A0 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
EE05020B1 (et) Glburiidi ravimkoostis
NO20035627D0 (no) Farmasöytisk formulering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DE50209245D1 (de) Neuroprotektives medikament
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
SI1475379T1 (sl) Uporaba derivatov skopinskega estra za pripravo zdravil
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
DE60216321D1 (de) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoä4,5-büindol-1-karboxamid-derivate, ihre herstellung und therapeutische verwendung
EP1413314A4 (en) MEDICAL COMPOSITIONS

Legal Events

Date Code Title Description
HC1A Change of owner name